Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
Laura C KennedyJun LuSydney KuehnArturo B RamirezEdward LoYao SunLance U'RenLaura Q M ChowZhengjia ChenPetros D GrivasEric P KaldjianVijayakrishna K GadiPublished in: Targeted oncology (2022)
Based on these results, CTC PD-L1 and IRF-1 expression is of interest in identifying ICI resistance and warrants further study.